




Healthcare Industry News: Magnetic Resonance Imaging
News Release - August 16, 2007
Covidien's MRidium Infusion Pump Delivers Industry-Leading Functionality for Magnetic Resonance Imaging
Children's Hospital Boston selects feature-rich, non-magnetic MRI infusion pump offered by Covidien, formerly Tyco HealthcareST. LOUIS--(HSMN NewsFeed)--Covidien Ltd. (NYSE: COV, BSX: COV) today announced the availability of several enhancements for its MRidium(TM) MRI Infusion System, which is the industry's first and only non-magnetic IV infusion pump. Specifically designed to address the challenges of the Magnetic Resonance Imaging (MRI) suite, the pump now has additional features that help operators administer intravenous medication more efficiently.
"The MRidium(TM) Infusion Pump is the state-of-the-art intravenous infusion pump in the MRI environment," said Keira P. Mason M.D., Director of Radiology Anesthesia at Children's Hospital Boston. "It is easy to use and accurate, and it has preprogrammed drug libraries - all of which make it appropriate for the delivery of an intravenous sedative or general anesthetic."
Compatible with magnets up to 3 Tesla and cleared for operation at the 10,000 Gauss Line, the MRidium(TM) pump helps shorten the distances between the pump and the patient, eliminating the need for tubing-intensive workarounds employed to keep traditional IV pumps outside of the strong magnetic fields of MRI systems.
In the latest version of software, the MRidium(TM) MRI Infusion System includes a library of drugs commonly initiated in the MRI suite, along with an integrated dose rate calculator to aid in accurate and efficient dispensing of medication. The new feature enables several key capabilities:
- Provides the ability to deliver a bolus in the drug calculator mode, while the pump is running - an important feature for delivering sedation medications;
- Allows delivery of drugs in volumes of less than 1 ml, which is particularly useful for pediatric patients where smaller volumes of drugs are commonly required;
- Allows drugs to be administered in Volume-Over-Time Mode, which is important for some cardiac MR stress test studies.
Additionally, the MRidium(TM) Infusion System features a wireless remote control that enables medical professionals to operate the system from the control room. The clinician no longer has to enter the scan room to adjust infusion parameters because the wireless remote can be used to titrate a patient's medication from the control room, eliminating the need to interrupt procedures. The pump also includes a microbore vented syringe infusion set that allows drug flow from the syringe into the IV tubing for accurate drug delivery while minimizing waste.
To learn more about the MRidium(TM) MRI Infusion system, please contact your local Covidien Sales Representative or visit our web site at www.imaging.mallinckrodt.com
The MRidium(TM) Infusion System is manufactured by IRadimed Corporation of Winter Park, Fla. It is distributed exclusively throughout North America by Covidien's Imaging Solutions business, which is based in St. Louis. Covidien's Imaging Solutions, formerly known as Mallinckrodt Inc., brings more than 90 years of experience in medical imaging.
ABOUT COVIDIEN
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines, including Surgical Devices, Energy-Based Devices, Respiratory and Monitoring Solutions, Patient Care and Safety Products, Imaging Solutions, Pharmaceutical Products and Medical Supplies. With 2006 revenue of nearly $10 billion, Covidien has more than 43,000 employees worldwide in 57 countries, and its products are sold in over 130 countries. Please visit www.covidien.com to learn more about our business.
(1) Source: The U.S. Imaging Market Guide, 2006 by AMR/Arlington Medical Resources, Inc.
MRidium is a trademark of IRadimed Corporation.
Source: Covidien
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.